
Associate Director, Translational Medicine Lead
AstraZeneca
Summary
We are seeking a highly motivated Associate Director, Translational Medicine Lead to develop and lead hypothesis-driven biomarker strategies and translational science across our B-cell malignancy programs, spanning B-cell Acute Lymphoblastic Leukemia (B-ALL), B-cell Chronic Lymphocytic Leukemia (B-CLL), and Non-Hodgkin Lymphoma (NHL), including combination therapy studies. The role will translate disease biology and therapeutic mechanism into actionable plans for patient stratification/selection, target engagement, pharmacodynamic assessment, depth and durability of response, and mechanisms of resistance. This is a 100% Translational Medicine role supporting large molecules (T-cell engaging bispecifics, ADCs, monoclonal antibodies), small molecules, and cell-based therapies.
Job description
Role Summary
We are seeking a highly motivated Associate Director, Translational Medicine Lead to develop and lead hypothesis-driven biomarker strategies and translational science across our B-cell malignancy programs, spanning B-cell Acute Lymphoblastic Leukemia (B-ALL), B-cell Chronic Lymphocytic Leukemia (B-CLL), and Non-Hodgkin Lymphoma (NHL), including combination therapy studies. The role will translate disease biology and therapeutic mechanism into actionable plans for patient stratification/selection, target engagement, pharmacodynamic assessment, depth and durability of response, and mechanisms of resistance. This is a 100% Translational Medicine role supporting large molecules (T-cell engaging bispecifics, ADCs, monoclonal antibodies), small molecules, and cell-based therapies.
Key Responsibilities
- Develop and own translational science strategies for assigned B-cell malignancy programs from preclinical stages through Phase 1/2 and Phase 3 clinical studies.
- Generate and integrate disease linkage data to support indication selection, patient stratification, and targeted population definition.
- Measure and interpret target engagement, pharmacodynamic biomarkers, and mechanism of action data to inform dose selection and clinical decision-making.
- Define and investigate mechanisms of resistance to B-cell targeted therapies using longitudinal and relapse clinical samples.
- Analyze B-cell tumor biology, cancer pathway interactions, and tumor microenvironment features to guide rational drug combination strategies.
- Lead development and deployment of fit-for-purpose translational assays (flow cytometry, IHC/IF, molecular, MRD-adjacent panels) internally and through external CRO/laboratory partners.
- Collaborate with Precision Diagnostics to ensure appropriate sample collection, traceability, and documentation; support CDx pathway discussions.
- Contribute translational and biomarker content for regulatory interactions and filings.
- Represent the TM function within program-level cross-functional teams as a scientific partner to Clinical Development, Oncology Research, Clinical Operations, and Product Development.
- Embed biomarker strategies and translational endpoints into clinical study protocols, sample collection manuals, statistical analysis plans, and data delivery cadences.
- Contribute to translational strategy across the broader B-cell hematology portfolio.
- Partner with preclinical discovery teams to ensure translational insights inform early compound selection and target validation.
- Contribute to and ensure the quality of TM clinical study reports, data reviews, scientific presentations, and recommendations for program governance and Go/No-Go decisions.
- Integrate translational findings across experiments and studies to build a coherent scientific narrative.
- Communicate biomarker data clearly to internal stakeholders including program governance forums and leadership teams.
- Contribute to scientific publications and conference presentations; represent AstraZeneca in external scientific forums.
Required Qualifications
- Established knowledge of B-cell malignancy biology spanning leukemia (B-ALL, B-CLL) and lymphoma (NHL), including disease pathogenesis, standard-of-care landscape, and mechanisms of therapeutic resistance.
- In-depth understanding of immunology and the tumor microenvironment in B-cell cancers.
- Demonstrated experience with T-cell engaging bispecifics (e.g., CD3-targeting bispecifics, BiTEs) in an oncology/hematology development context.
- Demonstrated experience with antibody-drug conjugates (ADCs) in a hematology or oncology development context.
- PhD in a relevant biological science (hematology-oncology, immunology, oncology, molecular biology, or related field); postdoctoral and/or industry experience required.
- 3-5 years experience contributing to early phase oncology clinical trials, including biomarker plan development, protocol input, and sample analysis.
- Demonstrated expertise in biomarker technologies such as flow cytometry, immunohistochemistry, molecular profiling, NGS, ctDNA, MRD assessment, cytokine/immune profiling, and other omics-based approaches.
- Emerging understanding of the end-to-end clinical development process and the strategic role of biomarkers at each stage.
- Ability to work independently and deliver translational programs with regular managerial support.
- Proven ability to operate effectively and demonstrate scientific leadership within cross-functional program teams in a matrixed pharma or biotech environment.
- Excellent communication and presentation skills for internal stakeholders and emerging external scientific audiences.
Preferred Qualifications
- Experience with small molecule hematology therapeutics in B-cell malignancies (e.g., BTK inhibitors, BCL-2 inhibitors) and familiarity with combination treatment strategies.
- Exposure to cell therapy programs (CAR-T or other engineered cell therapies) in B-cell leukemia or lymphoma.
- Familiarity with Minimal Residual Disease (MRD) methodologies (flow cytometry and/or NGS-based) in leukemia or lymphoma clinical development.
- Experience integrating multi-omic biomarker data to support clinical decision-making across combination regimens.
- Familiarity with regulatory expectations for biomarker analytical validation and CDx development.
- Early experience mentoring junior scientists; interest in contributing to team capability development.
Requirements
- Established knowledge of B-cell malignancy biology spanning leukemia (B-ALL, B-CLL) and lymphoma (NHL)
- In-depth understanding of immunology and the tumor microenvironment in B-cell cancers
- Demonstrated experience with T-cell engaging bispecifics in oncology/hematology development
- Demonstrated experience with antibody-drug conjugates (ADCs) in hematology or oncology development
- PhD in a relevant biological science (hematology-oncology, immunology, oncology, molecular biology, or related field)
- Postdoctoral and/or industry experience required
- 3-5 years experience contributing to early phase oncology clinical trials
- Expertise in biomarker technologies such as flow cytometry, immunohistochemistry, molecular profiling, NGS, ctDNA, MRD assessment, cytokine/immune profiling, and omics-based approaches
- Understanding of the end-to-end clinical development process
- Ability to work independently and deliver translational programs
- Proven ability to demonstrate scientific leadership within cross-functional program teams in a matrixed pharma or biotech environment
- Excellent communication and presentation skills
Benefits
- 401(k) Retirement Programs
- Paid Time Off
- Health, Dental & Vision Coverage
- Short-Term Incentive Bonuses
- Equity-Based Awards
Company overview
AstraZeneca is a global, science-led, patient-focused pharmaceutical company dedicated to accelerating the delivery of life-changing medicines that create enduring value for patients, society, and shareholders. With a workforce of over 94,300 employees worldwide, the company operates across three core therapy areas: Oncology, BioPharmaceuticals (including Cardiovascular, Renal & Metabolism, Respiratory & Immunology), and Rare Disease. Headquartered in Cambridge, UK, AstraZeneca maintains strategic R&D centers in Cambridge, Gaithersburg (US), Boston (US), Gothenburg (Sweden), Shanghai, and Beijing. The company generated $54.1 billion in total revenue in 2024 and invested $13.6 billion in scientific research and development. AstraZeneca's bold aspiration is to be pioneers in science, lead in disease areas, and transform patient outcomes, with a goal to launch 20 new medicines and achieve $80 billion in total revenue by 2030. The company is recognized for its commitment to sustainability, health equity, and creating an inclusive work environment where diverse perspectives drive innovation.